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INTRODUCTION 
 There are about 2.5 to 3 million HIV patients in India and the calculated  
prevalence in Tamilnadu is about 0.34 percent1. Survival of HIV patients has 
improved significantly with better control of opportunistic infections and 
administration of Highly Active Anti-Retroviral Therapy (HAART)2. Real 
incidence of AIDS-associated cancers in Indians is not known. There are only 
few reports in Indian literature. It may be roughly 3-4 per cent in Indians2, 3. 
 Since the onset of the HIV/AIDS pandemic in the early 1980s, HIV 
infection and cancer have been closely related. Several reasons explain this 
phenomenon; the immune suppression induced by HIV favors occurrence of 
cancers such as high-grade non - Hodgkin’s  lymphoma(NHL); the oncogenic 
nature of  certain viruses, which directly cause cancers such as HHV8 and 
Kaposi’s sarcoma(KS) and human papilloma virus and cervical cancer in 
women or rectal squamous cell cancer in men. Because many of these tumors 
have such a high prevalence in HIV-infected persons, they are included as part 
of the clinical definition of AIDS and are reported formally as “AIDS-defining 
malignancies”. Secondly, the increase in survival of HIV-infected patients has 
led to the observation in several cohort studies that an increasing number of 
“non-AIDS-defining malignancies”, such as Hodgkin’s disease (HD), invasive 
anal carcinoma, lung carcinoma, skin cancer and hepatocarcinoma, are now 
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being reported at higher than expected frequencies compared to rates observed 
in the general population. 
 The hallmark of HIV disease is a profound immunodeficiency resulting 
primarily from a progressive quantitative and qualitative deficiency of the 
subset of T lymphocytes referred to as helper T cells. This subset of T cells is 
defined phenotypically by the presence on its surface of the CD4 molecule 
which serves as the primary cellular receptor for HIV. It has been observed that 
malignancies may be related to two different profiles: time spent with a low 
CD4 cell count and exposure to a high viral load4. Both conditions are 
associated with a higher risk for developing AIDS-related cancers while the 
time spent with CD4 counts under 500cells/mm3 or with viral load greater 
than500copies/ml are associated with a higher risk for non-AIDS-defining 
malignancies 5. 
In the pre-HAART era, treatment for HIV associated Malignancy 
mandated risk assessment, comparing the chance of successful therapy against 
the possibility of worsening severe immunodeficiency leading to mortality. A 
variety of treatment approaches were evaluated including standard-dose, 
reduced-dose, and even escalated dose chemotherapy 6,7,8,9.Outcomes were poor 
regardless of treatment choice with complete response rates of about 50% and 
median survivals in the 5 to 8month range 6,7,8.  
 3
             The optimal management of HIV associated Malignancies is 
challenging since we have  to  deal  with  the  immune  compromise  associated  
with HIV and the natural history, clinical features and associated  
complications arising due to the primary tumor – both  solid  and   
hematological  malignancies – including  tumor  site , nodal  and  metastatic  
stage. 
Implementation of highly active antiretroviral therapy (HAART) has 
changed the epidemiology, clinical outcome and therapeutic approach of HIV-
associated malignancies. The use of concomitant chemotherapy and HAART 
has been demonstrated to be feasible and effective in reducing morbidity 
associated with opportunistic infections and to improve overall survival in 
patients with HIV-related malignancies10,11. 
At the department of Medical Oncology, Madras Medical College, 
Chennai, about   2200-3000 new patients are registered annually. Of these, the 
incidence of HIV and Malignancy has not been evaluated but it has been 
observed that there is a noticeable increase in the incidence in the past few 
years.  
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REVIEW OF LITERATURE 
Patients  infected  with  human  immunodeficiency  virus (HIV)  are  at  
a significantly  increased  risk  of  developing  cancer  compared  with  the  
general population. In fact, the  onset  of  the  acquired  immune  deficiency  
syndrome (AIDS) epidemic  was  heralded  by  an  increased  incidence  of  a  
rare malignancy, Kaposi’s  sarcoma (KS), in 198112, 13.  In  1982, the  U.S. 
Centers for  Disease  Control  and  Prevention (CDC)  proposed  the  initial  
case  definition for  AIDS,  including  such  AIDS - defining  malignancies  as  
KS  and  primary central  nervous  system  lymphoma   (PCNSL) 14.  
Subsequent  revisions   of  the  CDC  definition  for  AIDS  resulted  in  the  
addition  of  non - Hodgkin’s lymphoma  (NHL)  not  restricted  to  the  CNS15  
and  invasive  cervical  cancer16.  
In addition to the aforementioned AIDS-defining malignancies, patients 
infected with HIV are also at increased risk for developing certain non-AIDS-
defining cancers.  In  large  database  studies  of  linked  AIDS   and    cancer  
registries , the  overall  rates  of several neoplasms including Hodgkin’s 
lymphoma,  invasive  anal  carcinoma,  multiple  myeloma,  leukemia,  lung 
cancer,  as  well  as  malignancies  involving  the  oral cavity,  lip,  esophagus, 
stomach,  liver,  pancreas,  larynx,  heart, vulva,  vagina,   kidney,  and  soft  
tissues (e.g., leiomyosarcoma  in  children),  were  found  to  be  in   excess  in 
patients  infected  with  HIV 17-20.  However,  unlike  the  AIDS-defining 
malignancies,  the  association  of  many  of  these  non-AIDS-defining  
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cancers with  progressive  immunosuppression  has  not  been  established 17-21. 
Other oncogenic  mechanisms  are  therefore  likely  involved,  including  
confounding epidemiologic  associations  (e.g., smoking)  or  viral  co-
infections  (e.g., human papilloma  virus). The  most common  epithelial  
cancers found in  the general  population  do  not  appear  to  occur  more  
frequently  in  HIV-positive patients,  including  carcinoma  of  the  breast,  
prostate,  and  colon 17, 18, 20, 21. 
            With  the  advent  of  highly  active  antiretroviral  therapy  (HAART),  
the morbidity  and  mortality  associated  with  HIV  infection  dramatically  
improved 22. As  a  result  of  the  immune  reconstitution  afforded  by  
effective  combination  antiretroviral  therapies,  the  epidemiological  and  
clinical  profile  of  cancers  in  the  setting  of  HIV  infection  also  changed. 
While  significant decreases  in  certain  AIDS-defining  cancers  such  as  KS  
have  been  reported, similar  declines  for  other  malignancies  such  as   AIDS 
– related  lymphoma (ARL)  are  less  evident 22, 23.  Moreover,  with  patients  
now   living  longer with  chronic  HIV  infection  and  sustaining  fewer  
opportunistic  infections  in the  HAART  era,  malignancy  in  this  population  
is  becoming  an  increasingly prominent  cause  of  death  in   the  later  stages  
of  AIDS 5, 24.  Despite  the emergence  of  AIDS-related  cancers  in  the  
HAART  era,  concomitant  advances  in  chemotherapy,  antiretroviral  drugs,  
and  supportive  care  protocols are  allowing  for  more  aggressive  
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management  of  AIDS-related  cancers compared  with  the  pre-HAART  
years 25.  
The  role  of  CD4+  cell  count  and  HIV-1  RNA  level  in  the 
incidence  and  outcome  of  nADCs  remains  unknown.  However,  D:A:D 
cohort investigators   reported  that  a  low  CD4+  cell  count  is  a  strong 
independent  risk  factor  for  death  attributable  to  both  ADC  and  
nADC26.The  D:A:D  investigators  also  found  that  age  and  long – term  
HAART  use are  associated  with  increased  risk  of  death  attributable  to  
nADCs.  These results  were  confirmed  by  similar  findings  in  the  French  
ONCOVIH  study, which  found  that  CD4+  cell  count  and  HIV-1  RNA  
level  predicted  risk  of nADC27 , and  in  a  British  cohort  study,  which  
found  that  NNRTI  exposure and  low  nadir  CD4+  cell  count  are  
associated  with  increased  risk  of nADCs28.  
Crum-Cianflone  and  colleagues 2  analyzed  incidence  of  ADC and  
nADC  during  4  clinical  periods: - the  early  pre-HAART  era (1984-1990), - 
the  late  pre-HAART  era  (1991-1995), -  the  early  post-HAART  era (1996-
2000),  and -  the  late  post - HAART  era  (2001-2006). The investigators 
concluded that the incidence of Non-AIDS–Defining  cancers was increasing,  
constituting  majority  of  cancer  cases  despite the  use  of  HAART.  The  
investigators  also  assessed  whether   CD4+  cell count,  HIV-1  RNA  level,  
and  antiretroviral  exposure  predicted  cancer occurrence.  This  was a 
retrospective  analysis  of   US  military  beneficiaries  benefits from  23  years  
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of  follow-up  (33,486 person-years)  on  4498  HIV-infected individuals.  
However,  this  is  a  very  distinct  population,  notable  for  free access  to  
health  care,  geographic  variability,  stable  health  insurance  over many  
years,  early  diagnosis  of  HIV  because  of  routine  screening , and  unique  
demographics  ( median  28 years  of  age  at  HIV   diagnosis, 91.0% male,  
43.5%  white,  45.3%  black,  and  76.6%  of  HIV  diagnoses  before  1996).  
The investigators did not report the mode of HIV exposure.   
           A  shortcoming  of  this  analysis  was  the  absence  of  HIV-1  RNA  
from the  multivariate  analysis  because  28%  of  patients  did  not  have  
HIV-1 RNA data  ( probably  because  68%  of  the  cancers  developed  in  the  
pre-HAART era).  Nadir  CD4+  cell  count  was  also  not  analyzed  or  
reported . Other unreported  and  unanalyzed  data  include  hepatitis B  and  C  
co infection, smoking  rate,  alcohol  use,  and  injection  drug  use.  This  
unique  cohort  allowed  for  detailed  and  complete  follow-up  of  patients  
before  and  after  cancer  diagnosis.  However,  results  from  this  study  may  
be  difficult  to generalize  to  other  HIV  patient  groups.   
With  those  limitations  in  mind,  this  cohort  study  yielded  several 
notable  findings.  First,  as  noted  above,  the  majority  (68%)  of  the  cancers 
developed  in  the  pre-HAART  era.  The  rate  of  ADCs  peaked  during  the  
late pre-HAART  era  at  14.2  (per 1000 person-years)  and  declined  to  5.4  
in  the early  post-HAART  era  and  to  2.7  in  the  late  post-HAART  era.  
The  opposite  was  true  for  nADCs  (including  skin  cancers),  which  have  
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risen  in recent  years:  2.9  in  the  early  pre-HAART  era,  2.8  in  the  late  
pre-HAART era,  4.2  in  the  early  post-HAART  era,  and  6.7  in  the  late  
post-HAART era. Overall,  the  proportion  of  cancers  classified  as  nADCs  
increased  from  20% in  the  pre-HAART  era  to  71%  in  the  late  post-
HAART era (P < .0001).   
 These  trends  are  confirmed  by  individual  cancers  in  each category  
(Kaposi’s  sarcoma  and  non-Hodgkin’s  lymphoma  among  ADCs, and anal,  
prostate,  renal,  and  Hodgkin’s  disease  among  nADCs)  but  with  small 
sample  sizes  (except  for  anal  carcinoma  with  a  significant  13-fold  
increase over  the  study  period;  P = .001).  Notably  absent  were  large  
numbers  of  lung cancer  and  liver  cancer, two  problematic  cancers  in  most  
other   non- HIV  cohorts.  
Not  surprisingly,  ADCs  were  associated  by  multivariate  analysis  
with  a non  cancer  AIDS  diagnosis,  lower  CD4+  cell  counts,  higher  HIV-
1  RNA levels,  and  lack  of  HAART.  Older  age  at  HIV  diagnosis  was  
significantly associated  with  increased  risk  of  ADCs  by  univariate  
analysis  and  even  more  strongly  associated  with  nADCs  (hazard  ratio: 
2.15/10  years  for  nADC; hazard  ratio: 1.25/10  years  for  ADC).  These  
findings  confirmed  results  of  other cohort  studies 28,29,30 . 
It was also seen that CD4+  cell  counts  at  ADC  diagnosis  rose  
substantially (but  not  significantly)  during  the  4  study  periods,  with  
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medians  of   40, 80, 44,  and  242  cells/mm3,  respectively (P = .14).  This  is  
an  interesting  trend  for practitioners  who  are  finding  that  ADCs  occur  at  
higher  CD4+  cell  counts  in  the  current  era  probably  because  of  a  shift  
from  Kaposi’s  sarcoma  and primary  central  nervous  system  lymphoma  to  
non-Hodgkin’s lymphoma. However, two recent  reports  described  substantial  
Kaposi’s  sarcoma  disease  among   patients  with  high  CD4+  cell  counts  
receiving  HAART 31,32 . Among  nADCs,  no  association  was  found  
between  CD4+  cell  count, HAART  use,  or  prior  non cancer  AIDS  
diagnoses -  a  finding  that  contradicts results  of  the  ONCOVIH  study 27  
and  a  report  by  Powles  and colleagues 28.  But  these  new  results  are  
limited  by  the  small  number  of non-skin cancer  nADCs  in  the  study 2.  
Definition         
The  current  CDC  classification  system  for  HIV-infected  adolescents  
and  adults  categorizes  persons  on  the  basis  of  clinical  conditions  
associated with  HIV  infection  and  CD4+  T lymphocyte  counts.  The  
system  is  based  on three  ranges  of  CD4+  T lymphocyte  counts  and  three  
clinical  categories  and  is  represented  by  a  matrix  of  nine  mutually  
exclusive  categories (Table 1).  
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TABLE 1 
 Clinical Categories 
CD4+ T Cell 
Categories 
A -asymptomatic, 
Acute (Primary) 
HIV or PGL 
B -Symptomatic, 
Not A or C 
Conditions 
C -AIDS-
Indicator 
Conditions 
>500/microL A1 B1 C1 
200–499/microL A2 B2 C2 
<200/microL A3 B3 C3 
 
TABLE 2     
Category A: Consists  of  one  or  more  of  the  conditions  listed  below  in  an 
adolescent  or  adult  (>13 years)  with  documented  HIV  infection. Conditions 
listed  in  categories B  and  C  must  not  have  occurred.  
Asymptomatic HIV infection  
Persistent generalized lymphadenopathy  
Acute (primary) HIV infection with accompanying illness or history of 
acute HIV infection 
Category B: Consists  of  symptomatic  conditions  in  an  HIV-infected 
adolescent  or  adult  that  are  not  included  among  conditions  listed  in  clinical  
category  C  and that  meet  at  least  one  of  the  following  criteria: (1) The  
conditions  are  attributed to  HIV  infection  or  are  indicative  of  a  defect  in  
cell-mediated  immunity;  or    (2) the  conditions  are  considered  by  physicians  
to  have  a  clinical  course  or  to require  management  that  is  complicated  by  
 11
HIV  infection. Examples  include, but are  not  limited  to, the  following:  
Bacillary  angiomatosis  
Candidiasis, oropharyngeal (thrush)  
Candidiasis, vulvovaginal; persistent, frequent, or poorly responsive to 
therapy  
Cervical dysplasia (moderate or severe)/cervical carcinoma in situ  
Constitutional symptoms, such as fever (38.5°C) or diarrhea lasting >1 
month  
Hairy leukoplakia, oral  
Herpes zoster (shingles), involving at least two distinct episodes or more 
than   one dermatome  
Idiopathic thrombocytopenic purpura  
Listeriosis  
Pelvic inflammatory disease, particularly if complicated by tuboovarian 
abscess  
Peripheral neuropathy 
Category C: Conditions listed in the AIDS surveillance case definition.  
Candidiasis of bronchi, trachea, or lungs  
Candidiasis, esophageal  
Cervical cancer, invasivea  
Coccidioidomycosis, disseminated or extrapulmonary  
Cryptococcosis, extrapulmonary  
Cryptosporidiosis, chronic intestinal (>1 month's duration)  
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Cytomegalovirus disease (other than liver, spleen, or nodes)  
Cytomegalovirus retinitis (with loss of vision)  
Encephalopathy, HIV-related  
Herpes simplex: chronic ulcer(s) (>1 month's duration); or bronchitis, 
pneumonia, or esophagitis  
Histoplasmosis, disseminated or extrapulmonary  
Isosporiasis, chronic intestinal (>1 month's duration)  
Kaposi's sarcoma  
Lymphoma, Burkitt's (or equivalent term)  
Lymphoma, primary, of brain  
Mycobacterium avium complex or M. kansasii, disseminated or 
extrapulmonary  
Mycobacterium tuberculosis, any site (pulmonarya or extrapulmonary)  
Mycobacterium, other species or unidentified species, disseminated or 
extrapulmonary  
Pneumocystis jiroveci pneumonia  
Pneumonia, recurrenta  
Progressive multifocal leukoencephalopathy  
Salmonella septicemia, recurrent  
Toxoplasmosis of brain 
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Using  this  system,  any  HIV – infected  individual  with  a  CD4+  T 
cell  count of  <200/microL  has  AIDS  by  definition,  regardless  of  the  
presence  of  symptoms or  opportunistic  diseases  (Table 2).  Once  
individuals  have  had  a  clinical condition  in  category  B,  their  disease  
classification  cannot  be  reverted  back to  category  A,  even  if  the  
condition  resolves;  the  same  holds  true  for category  C  in  relation  to  
category  B 33,34. 
All malignancies are grouped under category C. They may have any 
CD4+ count at presentation. Here in comes the question when and how to start 
HAART along with chemotherapy and prophylactic antibiotics.                        
When to Start Antiretroviral Therapy 
The  CD4+ T cell  count  is  the   laboratory  test  generally  accepted  as  
the best  indicator  of  the  immediate  state  of  immunologic  competence  of  
the patient  with  HIV  infection 34,35,36.  This  measurement,  which  can  be  
made  directly or  calculated  as  the  product  of  the  percent  of  CD4+ T cells  
(determined  by flow  cytometry)  and  the  total  lymphocyte  count  has  been  
shown  to  correlate very  well  with  the  level  of  immunologic  competence. 
Patients  with  CD4+ T cell counts <200/microL  are  at  high  risk  of  disease  
from  P. jiroveci,  while patients  with  CD4+ T  cell  counts <50/microL  are  
at  high  risk  of  disease  from  CMV,  mycobacteria  of  the  M. avium 
complex (MAC)  and/or  T. gondii . Patients  with  HIV  infection  should  have  
CD4+ T cell  measurements performed  at  the  time  of  diagnosis  and  every  
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3–6 months  thereafter.  More frequent  measurements  should  be  made  if  a  
declining  trend  is  noted. 
 According  to  most  guidelines 34,35,36, a  CD4 T cell  count 
<350/microL  is an  indication  for  consideration  of  initiating  ARV  therapy,  
and  a  decline  in CD4+ T  cell count of  >25%  is  an  indication  for  
considering  a  change  in therapy.  Once  the  CD4+ T cell  count  is  
<200/microL,  patients  should  be placed  on  a  regimen  for  P. jiroveci  
prophylaxis,  and  once  the  count is <50/microL,  primary  prophylaxis  for  
MAC  infection  is  indicated.  
CIPRA HT-00137 and  SMART 38  and  other  randomized  trials 39-46  
study  showed   a trend of  lower  risk  of  serious AIDS- and  non-AIDS-
related  events  in  those  who  initiated  therapy immediately  compared  with  
those  who  deferred  therapy  until  CD4 count dropped to <250 cells/mm3 (p 
= 0.06) 38.  Collectively,  these  studies   support the  recommendation  that  
ART  should  be  initiated  in  patients  with  a  history of  an  AIDS-defining  
illness  or  with  a  CD4  count <350 cells/mm3. 
The  incidence  of  non-AIDS  malignancy  in  HIV-infected  subjects  is 
higher  than  in  matched  HIV-uninfected  controls 47.  Large  cohort  studies  
of mostly  patients  receiving  ART  have  reported  a  consistent  link  between  
low CD4 counts (<350−500 cells/mm3)  and  the  risk  of  AIDS  and/or  non-
AIDS-defining  malignancy 26,48-52.  The  ANRS C04  Study  demonstrated  a 
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statistically  significant  relative  risk  of  all  cancers  evaluated  (except  for 
anal carcinoma)  in  patients  with  CD4  counts <500 cells/mm3  compared 
with patients  with  current  CD4  counts  >500 cells/mm3  and  a  protective  
effect  of ART  for  HIV-associated  malignancies 50.  This  potential  effect  of  
HIV-associated  immunodeficiency  is  particularly striking  with  regard  to  
cancers associated  with  chronic  viral  infections  (e.g., HBV, HCV, human 
papilloma virus [HPV],  Epstein-Barr virus [EBV],  human herpes virus-8 
[HHV-8]) 53-54. Cumulative  HIV  viremia  itself  may  also  be  associated  with  
the  risk  of  non-Hodgkin  lymphoma  and  other  AIDS-defining  
malignancies,  independent  of other  factors 52, 55.  Together  this  evidence  
suggests  that  initiating  ART  to suppress  HIV  replication  and  maintain  
CD4  counts  at  above  350–500 cells/mm3  may  reduce  the  risk  of  both  
AIDS-defining  and  non-AIDS-defining  malignancies . 
Randomized  Trials  in  HIV  Associated  Malignancies 
Prior  to  the  advent  of  HAART,  patients  with  AIDS-related  NHL  
were managed  with  low-dose  regimens  due  to  concerns  of  unacceptable  
toxicity 56.  Survival at 2 years was approximately 10%.  
With the advent of HAART, groups began combining HAART with 
cytotoxic chemotherapy. The  first  report  of  a  series  including  patients  
treated  with  chemotherapy  and  HAART  described  an  alternating  weekly 
chemotherapy   regime  using  bleomycin, etoposide, vincristine, methotrexate,  
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prednisolone/cyclophosphamide,  doxorubicin (BEMOP/CA)  in  patients  with  
a  good  prognosis. Around half of these patients  were  receiving  HAART, 
and  the  overall  2-year  survival  rate  was  46%(95% CI27%–65%),with  a  2-
year  lymphoma-specific  survival of  59%(95%CI 27%–65%) 57. 
The  feasibility  of  combining  chemotherapy  with  HAART  therapy  
was  formally  explored  in  the  AIDS  Malignancy  Consortium005(AMC005)  
trial,  which  compared  CHOP  chemotherapy  at  a  reduced  dose  (mCHOP)  
or  full-dose  CHOP, with  concomitant  HAART  therapy  ( stavudine, 
lamivudine, and indinavir)  being  given  to  all  patients 58. 
They  reported  overall  response  rates  for  mCHOP  and  full-dose  
CHOP  of  60% (95%  CI45%–75%)   and  57% (95%  CI38%–77%), 
respectively (p=0.79), although  the  complete  response  rate  was  
significantly  higher  in  the  full-dose  CHOP  arm  (48%, as  compared  to  
30%  in  mCHOP). No  long-term  outcome  data  have  been  reported  for  this  
group  of  patients  .  There  were  no  significant  differences  in  grade  3 and 4  
toxicities observed in  the  two  groups.  Furthermore,  HIV  viral  loads  
declined  and  CD4 counts  increased  significantly  despite  the  concurrent  
use  of  chemotherapy. 
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TABLE 3 
Summary  of  published  phase II/III  trials  in  the  post-HAART  era 
Chemotherapy 
Regimen 
(reference) 
N Receiving 
HAART 
Complete 
response 
rate 
Median 
survival 
Overall 
Survival 
Low dose   
 m-BACOD 9 
98 Optional 41% 35weeks 
(95% CI 30–
45%)  
1year:27% 
2year:11% 
Standard dose 
m-BACOD 9 
94 Optional 52% 31weeks 
(95% CI 22–
42%) 
1year:24% 
2year:7% 
BEMOP-CA 57 30 50% 60%  2year:46% 
(95%CI27–65%) 
CHOP 
mCHOP 58 
25 
40 
100% 
100% 
48% 
30% 
  
CHOP 59 17 100% 75%  2yearprobability:
0.59(95%CI0.31–
0.87) 
CHOP    
m-BACOD 
MA-COP-B 
ACVB 60 
44 82% 52% 
HAART 
responders
:71% 
HAART-
failed/ 
naıve:30%
360days, 
HAART-
treated: 
425days 
(95%CI241–
609) 
1year(cumulative
probability):0.49 
HAART-
treated:0.51 
Virological 
response to 
HAART:0.84 
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CHOP 61 24 100% 50%  2year:55% 
DA-EPOCH 62 39  0  74%  60% (at median 
follow-up of  
53months) 
CDE 63,64 55 100% 44% 13.7months 1year:57% 
2year:45% 
 
CHOP(Liposom
aldox) 65 
24 100% 75% 413.4months 1year:58% 
CDE + 
rituximab 66 
74 76% 70%  2years(estimated)
:64% 
CHOP 67 
CHOP+ 
rituximab 
50 
99 
100% 
100% 
47% 
58% 
110 weeks 
139 weeks 
NS 
NS 
CHOP/ACVB-P   
68 
35 100% 54% 22months 1year:54% 
2year:49% 
 
These  data  were  supported  by  a  further  study  which  looked  at  the  
effect  of  HAART  on  the  response  to  treatment  and  survival  in  patients  
with  HIV-associated  NHL  treated  with  CHOP chemotherapy,  using  
historical  controls. This  revealed  that  patients  treated  with  CHOP  plus  
HAART  had  a  higher  response  rate  than  those  treated  with  CHOP  alone 
(75%vs.34%; p = 0.003) 59 .Other  studies  involving  CHOP  given  with  
HAART  have  reported  response  rates  of  47–75%,  with  median  survival  
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of  27months  and overall  survival of  58% and 55%  being   reported  at  one 
and two years,  respectively 61,65,67. The  substitution  of   liposome-
encapsulated  doxorubicin for  conventional  doxorubicin  in  the  CHOP  
regimen  does  not  appear  to  affect  the  efficacy  of  this  treatment 65.   
A   prospective  observational  study  of  44 patients  included  34  
treated  with  CHOP  and   the  remaining  10  with either  m-BACOD , 
modified m-BACOD,  methotrexate,  doxorubicin, cyclophosphamide, 
vincristine , prednisolone,  bleomycin (MA-COP-B)  or adriamycin,  
cyclophosphamide, vinblastine,  and  bleomycin(ACVB).  Eight  patients  in  
this  cohort  did  not  take  HAART.  The  study  reported  a  complete  
response  in  52%  of  patients,  with  a  complete  response  more  frequently  
seen  in  those  who  had  a  virological  response  to  HAART ( 70%  as  
opposed  to  30%  in  non-responders. Multivariate  analysis  revealed  that  
virological  response  to  HAART  was  the  only  variable  associated  with  
tumour  response  ( OR6.36, 95%  CI1.56–25.81) 60. This finding  could  be  
related   to  the  fact  that  those  who  had  a  virological  response  received  a  
significantly higher  dose  intensity  of  chemotherapy, compared  to  those  
who  did  not  respond  to HAART, due  to  the  possible  improvement  in  
haematopoiesis  given  the  inhibition  of  HIV. This  enabled  a  greater  dose  
density  of  chemotherapy  to be  delivered , which  is  a  known  factor  in  the  
outcome  of  NHL. The  estimated  overall  survival  for  all  patients  was  360 
days (95% CI 81–639), with a 1 year  cumulative  survival  probability  of  
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0.49;   however, In  the  HAART-treated  patients,  estimated   overall  survival  
was  425 days (95%  CI 241–609), with  a  1 year  cumulative  probability  of  
0.51, increasing  to  0.78  in  those  with  a  virological  response  to  HAART60. 
Preclinical  data  suggested  that  infusional  schedules  of  cytotoxic  
agents  might  have  a  therapeutic  advantage61. Two  infusional  chemotherapy 
regimens  have  been  investigated  in  AIDS-related  NHL,  namely:  
cyclophosphamide,  doxorubicin  and  etoposide (CDE)  administered  as  a  
96-h  continuous  infusion,  and  cyclophosphamide,  doxorubicin, etoposide,  
vincristine  and  prednisolone (EPOCH) . CDE  was  first  found  to  be  highly  
active  and  capable  of  producing  durable  remissions  in  HIV-related  NHL  
in  a  small  pre-HAART  era  study.  In this study, CDE  was  administered  to  
12  HIV-sero positive  and  two  HTLV-1-seropositive  patients. A complete  
response rate  of  71%  and  a  partial  response  rate  of  21% was observed. 
Median  survival  was  estimated  at  17.4 months, with seven of the 12 HIV-
positive  patients  alive  and  disease-free  at  a  median  follow-up  of  15 
months69. A  subsequent  report  of  25  patients  with  AIDS-related  
lymphomas  treated  with  CDE  plus  didanosine  produced  a  complete  
response  rate  of  58%  (95%  CI 38–78%)  and  a  median  survival  of  18.4  
months;  this  was  seen  as  a   major  advance  in  the  treatment  of  HIV  
related  NHL70.  The same schedule combined with saquinavir produced similar 
results. A comparison of patients treated with  CDE   revealed  improved  
overall  survival  with  the  concurrent  use  of  HAART  as  compared to  those  
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in  the  pre-HAART  group,  namely  those  patients  treated  with  didanosine 
(p=0.039) 63. Complete  response  rates  of  50%,  with  a  2-year survival  of  
61%  and  median  survival  of  26 months,  have  been  reported  by others  
using  this  regimen64. 
Treatment of  HIV-associated  NHL  with  omission  of  HAART 
Dose-adjusted  EPOCH (DA-EPOCH; etoposide, prednisone, 
vincristine, cyclophosphamide, and  doxorubicin) regimen  is  an  infusional  
regimen  developed  from  in vitro  studies  showing  that  tumor  cells  are  
relatively  less  resistant  to prolonged  low  concentration  exposure  to  the  
natural  product derived  agents  vincristine,  doxorubicin,  and  etoposide,  
compared with  brief  higher  concentration  exposure 71,72.  Clinically, DA-
EPOCH can overcome resistance to standard CHOP chemotherapy. A study  of  
DA-EPOCH  in  50  untreated  HIV-negative  patients  with  diffuse  large  B-
cell  lymphomas (DLBCLs)  showed   an  overall  and  progression-free  
survival  of  73% and  0%,  respectively,  at  5 years71,73.  The  dose-adjustment  
strategy  was  developed  to  reduce  hematopoietic  toxicity  while  
maintaining  maximum  dose  intensity  by   normalizing  drug  doses  to  the  
absolute  neutrophil  nadir73. 
        The  rationale  behind  interrupting  HAART   was  to  avert adverse  drug  
reactions  that  could  reduce  the  chance  of  cure.  In  addition ,  it  was  felt  
firstly  that  HAART  would  not  prevent  chemotherapy-induced  lymphocyte  
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depletion,  secondly  that  the  predicted  HIV  dependent  CD4 +   cell  loss  
during  the  16-week  period  of  HAART  would  be  relatively  small,  and  
thirdly  there  was  concern that  HAART  could  inhibit  lymphocyte  
apoptosis,  and  hence  impact  on the  efficacy  of  chemotherapy74. Other  
potential  reasons  to  consider  omission  of  HAART  for  patients  receiving  
chemotherapy  included  compliance  issues  in  the  setting  of  polypharmacy,  
as  well  as  problems   with  chemotherapy-induced  nausea,  vomiting  and  
mucositis which  may  reduce  ability  to  comply  with treatment75,76. 
         A  complete  response  was  achieved  by 29  patients (74%; 95% [CI]:58-
87) and  a  partial  response  was  achieved  by  5  patients  (13%) , for  a  total    
response  rate of  87%. Among  patients  with  CD4+ cells  more than 
100/mm3, 87%  achieved  a  complete  response, whereas  56%  of patients 
with  lower  CD4+ cell  counts  achieved  a  complete  response.  At  the  
median  potential  follow-up  of  53 months, the  progression-free  survival was 
73%  and  the  overall  survival  was  60%. When  analyzed  by  CD4+ cell  
number (  < or > 100cells/mm3),  the  overall  survival  rates  were  16%  and   
87%, respectively,  at 53 months. CD4 cells  decreased to a  median  of  189 
cells/mm3(range: +19  to -973)  by  cycle 6,  followed  by  recovery  to  
baseline  within  6 to 12 months77.         
            Dose  adjustment  with  antiretroviral  suspension  allowed full  delivery  
of  the  infused  agents,  while  minimizing  clinical  and   immune  toxicity. 
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Treatment  was  well  tolerated  and  the  incidence  of  serious  adverse   
effects  was  similar  to  standard  CHOP  chemotherapy. 
           These  results  also  raised  challenging  questions  about  the  role  of 
HAART  during  the  treatment  of  ARL. It  is  commonly  held  that  HAART  
is  necessary  to  prevent  uncontrolled  HIV  replication  and  loss  of  immune  
function  during  chemotherapy. A  recent  study  suggested  that  response  to  
HAART  is  essential  to  treat  ARL  with  curative  intent60. However,  the 
study  found that  antiretroviral  therapy  is not  required  during  chemotherapy  
to  achieve  a  high  overall  survival  and  post treatment  viral  control  and  
immune  recovery. Only  the  CD4+ cell  counts  and  involvement  of  the 
central  nervous  system  at  study  entry  were  independent  prognostic  factors  
in  the  study, both  of  which  are  interrelated  with  the  tumor  
pathobiology78,79,80. 
Role of rituximab in the treatment of  HIV-associated NHL 
The addition of rituximab (R) substantially improves response and 
progression-free survival in ARL, although in a randomized trial comparing 
CHOP with R-CHOP, these improvements were not statistically significant. 
Around 14% of patients receiving rituximab died of treatment-related 
infectious deaths, annulling any advantage to overall survival67. Yet, this trial 
documented a complete response rate that was 22% higher in the group that 
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received R-CHOP. Moreover, only 8% of the group that received R-CHOP had 
disease progression, compared with 21.6% of those receiving CHOP alone 81. 
A more recent phase II trial of R-CHOP in ARL found that there was no 
excess toxicity and documented a complete response rate of 77% and a 2-year 
survival rate of 75%82.  Three phase II trials of rituximab with CDE 
(continuous infusion during 96 hours of cyclophosphamide, doxorubicin, and 
etoposide), showed a complete response rate of 70% and both disease-free and 
overall survival of 55% at a median follow-up of 23 months was documented82. 
A phase II randomized trial of either R-dose adjusted (DA)-EPOCH (rituximab 
given with 96 hours of continuously infused etoposide, doxorubicin, and 
vincristine with oral prednisone and bolus cyclophosphamide dose-adjusted for 
tolerance) or DA-EPOCH followed by rituximab maintenance indicates a 1-
year progression-free survival of 80% in the R-DA-EPOCH arm and 72% in 
the arm of DA-EPOCH followed by rituximab83. There were no excess 
treatment-related complications. This latter study appeared to confirm the 
findings of a phase II trial of DA-EPOCH alone that reported a complete 
response rate of 74% and a disease-free survival and overall survival 92% and 
60%, respectively, at a median follow-up of 53 months 77. 
CD4 cell dynamics and chemotherapy 
The effect of chemotherapy on CD4 count and plasma HIV viral load 
has been investigated in some clinical trials. The results reported vary; some 
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studies have found an increase in the CD4 count on treatment (e.g.from  a 
median baseline value  of 138 (CHOP) and 122 (mCHOP) cells/mm3 to a 
median of 216 cells/mm3 after treatment58. In contrast, two other trials of 
chemotherapy alone found a decrease in CD4 cell count with treatment, with a 
mean change between commencement and completion of 47 cells/mm3 60 and a 
50% decrease in another84. In the CHOP and mCHOP trial, there were no 
differences in the CD4 and VL dynamics between the two chemotherapy 
arms58. With DA-EPOCH where HAART is discontinued, the CD4 count 
decreased by a median of 189 cells/mm3 (range +19 to-973) by the sixth cycle 
of treatment 62. 
Only one trial that combined chemotherapy and Rituximab has 
described CD4 and viral load changes. It showed a small drop in the median 
CD4 count between baseline and one month post treatment, from 161/mm3 to 
108/mm3. 
Non–AIDS-Defining Cancers in the Era of HAART  
        Non AIDS defining cancers have increased in the era of HAART. 
Although it may be premature to consider this an epidemic of cancer in 
HIV/AIDS, several factors suggest that the incidence of non AIDS-defining 
cancer in HIV/AIDS is likely to increase. The excess risk of certain non AIDS-
defining cancer is partly attributable to other risk factors for these tumors in 
HIV-infected patients, such as cigarette smoking. However, the risk of these 
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non AIDS-defining cancers does not appear to be fully explained either by 
these cofactors or HIV-related CD4 cell depletion. For example, the nearly 
fivefold excess lung cancer risk in HIV appears related to age and HAART use, 
but not to CD4 cell count, and the risk remains elevated at 2.5-fold more than 
the general population, even when adjusted for smoking85. Standardized to the 
background population the incidence for Hodgkin's lymphoma (HL) is also 
increasing in populations in which HAART is commonly available, increasing 
from eightfold to nearly 14-fold the expected incidence since HAART became 
available86. Indeed, recent studies indicate that cancer is now the most common 
cause of death in patients with HIV infection, and about half of these cancer-
associated deaths are caused by AIDS-defining malignancies and about half by 
non AIDS-defining cancer5, 87. 
No randomized studies have addressed the question of the best 
chemotherapy regimen for patients with nADC and HIV infection, and the data 
are derived mainly from non-randomized controlled trials or case series. 
Hodgkins lymphoma, anal cancers, germ cell tumors, NSCLC, HCC 
treatment are recommended according to British HIV Association Guidelines. 
There are no specific guidelines for tumors of breast, head and neck, 
melanoma, colon and other urological sites. 
For anal cancer, in phase II studies in HIV-positive individuals, the best 
outcomes appear to have derived from the use of combined modality therapy of 
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radiotherapy and concurrent chemotherapy88-93.  This generally has involved   
5-fluorouracil and mitomycin C, and concomitant radical radiotherapy to the 
pelvis (38-51 Gy in 20-30 fractions), with most patients receiving a perineal 
boost (10-18 Gy).There is no evidence that HAART can cause regression of 
anal cancer, but we recommend its use to prevent other infections, maintain 
CD4 cell count and suppress viraemia94,95. 
For Hodgkins lymphoma the recommendations are that all patients 
should be treated with HAART (level of evidence III B). 
First-line treatment: standard chemotherapy (ABVD) should be offered 
(level of evidence III b). More intensive chemotherapies (BEACOPP or 
Stanford V) might be considered in the context of a clinical trial (level of 
evidence III C) 96-98. 
Second-line treatment: salvage chemotherapy followed by high-dose 
chemotherapy and autologous stem cell transplantation should be strongly 
considered unless the patient has multiclass-resistant HIV with no remaining 
antiretroviral options (level of evidence III B) 99-102 
HIV Associated Malignancies : Do we need HAART 
A roundtable discussion convened at the Ninth International Conference 
on Malignancies in AIDS and Other Acquired Immunodeficiencies 
recommended that if a patient is tolerating a stable HAART regimen, it may be 
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reasonable to continue this during chemotherapy56. This panel also noted that it 
may be advisable to wait until after chemotherapy is completed for patients not 
already receiving antiretroviral therapy. 
Rationale of the proposed study 
        This study is built upon the evidence that HAART along with 
chemotherapy is the standard of care in HIV associated malignancies and 
standard dose of chemotherapy can be given. By the proposed study, the 
following objectives are being tested: 
1. CD4+ count during chemotherapy may vary and correlating it to response 
rate. 
2. An increase in CD4+ Count will result in decreased opportunistic infections 
and chemotherapy related toxicities. 
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AIM OF THE STUDY 
To evaluate the impact of chemotherapy and HAART on immunological 
parameters in all HIV associated malignancies.  
1. To describe the response after each cycle of chemotherapy and HAART with 
reference to CD4 count. 
2. To study the pattern of HIV patients presenting with AIDS defining cancers 
and non-AIDS defining cancers. 
3. To determine the feasibility of treatment delivery, patient tolerance, and 
acute toxicities. 
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MATERIALS AND METHODS 
PATIENT SELECTION 
1.Conditions for patient eligibility 
1.1 Pathologically (histologic or cytologic) proven diagnosis of primary solid 
or hematological malignancy and metastasis of unknown origin. 
1.2. Serologic proof of HIV (ELISA/TRIPLE RAPID TEST). 
1.3. All Stages of malignancy based upon the following minimum diagnostic 
work-up: 
    1.3.1. History / physical examination within 4 weeks prior to 
registration. 
     1.3.2. Imaging work-up with chest roentogram, usg –abdomen/ pelvis/ 
scrotum within 4 weeks prior to registration. 
    1.3.3. Chest/abdomen/brain/whole neck –CT or MRI wherever feasible 
within 4 weeks prior to registration. 
1.3.4. ECG/ECHOCARDIOGRAM within a week prior to registration. 
1.3.5. Endoscopy –upper or lower GI Scopy, Bronchoscopy whenever 
necessary within 4 weeks prior to registration. 
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1.3.6. Peripheral smear and bone marrow biopsy/smear whenever 
necessary within a week prior to registration. 
1.4. Zubrod/ ECOG performance status 0-2. 
1.5. Age: Above 10 and below 65. 
1.6. CBC/differential obtained within a week prior to registration on study, 
with or without  bone marrow involvement but with adequate bone marrow 
function defined as follows: 
     1.6.1. Absolute neutrophil count (ANC) _>1500 cell/mm3. 
     1.6.2. Platelets >100000 cells/mm3. . (Note:The use of transfusion or 
other intervention to achieve platelets >100000/mm3 is acceptable) 
     1.6.3. Hemoglobin >8.0g/dl. (Note:The use of transfusion or other 
intervention to achieve Hgb >8.0g/dl is acceptable). 
1.7. Additional laboratory studies obtained within 2 weeks prior to 
registration on study 
     1.7.1. Creatinine <1.5mg/dl 
     1.7.2. Bilirubin <1.5 x upper limit of normal. 
     1.7.3. AST <3x upper limit of normal. 
     1.7.4. Serum pregnancy test for women of childbearing potential. 
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     1.7.5. Serum lactate dehydrogenase (LDH) 
1.8. HBsAG   and HBC within 4 weeks prior to registration on study. 
1.9. Patient must provide Signed study-specific consent form prior to study 
entry. 
2.Conditions for patient ineligibility 
2.1. Malignancy confirmed patients but serologically negative for HIV.  
2.2. No prior chemotherapy for malignancy 
2.3. No prior radiation therapy 
2.4. Prior allergic reaction to the study drugs involved in this protocol.  
2.5. Severe, active medical comorbidity defined as follows 
        2.5.1 Unstable angina and/or congestive heart failure requiring 
hospitalization within the last 3 months 
       2.5.2. Transmural myocardial infarction within the last 6 months. 
       2.5.3. Chronic obstructive pulmonary disease exacerbation or other 
respiratory illness requiring hospitalization or precluding study therapy at the 
time of registration. 
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2.6. Pregnant women and nursing mothers and men who are sexually active and 
not willing/able to use medically acceptable forms of contraception;this 
exclusion is necessary because the treatment involved in this study may be 
teratogenic. 
2.7. Age above 65 years. 
2.8. Post transplant patients because the natural history and treatment modality 
may be different. 
METHODOLGY 
             All patients referred to our department with known HIV positivity and 
patients without known HIV status are referred for Elisa/Triple rapid test and 
are included in our protocol study.   
             All HIV Positive patients are then registered with ART centre and 
assessed for CD4 count routinely and viral load if possible. This study requires 
only CD4 count done at the time of registration and at the beginning of next 
chemotherapy. Staging of HIV infection was done with CD4+ counts. Serum 
LDH was estimated for evaluation of disease activity. Patient and relatives 
were given complete information about the nature of both the diseases, further 
plan of management and complications involved in this.  Different treatment 
options of highly active anti-retroviral therapy (HAART) were discussed with 
patients. Reverse transcriptase inhibitor (RTI) – or protease inhibitor (PI) based 
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antiretroviral therapy, interaction between chemotherapeutic agents, their 
toxicities were discussed in detail with the patient and relatives.  
PRETREATMENT EVALUATIONS 
1. Complete history and examination including height and weight with an 
assessment of patient’s performance status. 
2. All patients evaluated by a medical oncologist prior to study. 
3. Laboratory studies –within a week prior to treatment 
        3.1. CBC 
        3.2. Renal and liver parameters, LDH, Alkaline phosphatase, URIC acid, 
calcium, phosphorous, magnesium. 
4. Peripheral smear and bone marrow biopsy/smear in all hematological and 
small round cell solid tumors. 
5. Imaging studies-within 4 weeks prior to study  
-CT SCAN of brain, neck, chest and abdomen, spine and limbs 
wherever necessary. 
-Upper/lower GI endoscopy 
-Chest X ray 
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-All other data to stage malignancy with TNM classification or ANN 
ARBOR or other staging with respect to the disease concerned. 
6. Biopsy /cytology of the primary tumor 
7. Specific serum tumor markers to diagnose, stage, prognosticate and follow-
up. 
8. Immumohistochemistry / Flow cytometry to confirm and subtype 
hematological malignancy. 
9. Bone scan/ skeletal survey. 
10. HIV status confirmation and CD4 count. 
TREATMENT : HAART 
         According to the operational guidelines of NACO, the patients are 
initiated on HAART when the CD4 count is less than 200 or in severe/ 
advanced symptoms irrespective of CD4 count. All malignant patients are 
hence defined as advanced symptoms and are started on HAART. 
Principles for selecting the first-line regimen 
1.   Choose 3TC (lamivudine) in all regimens 
2.   Choose one NRTI to combine with 3TC (AZT or d4T) 
3.   Choose one NNRTI (NVP or EFV) 
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Fixed-dose combinations (FdCs) are preferred because they are easy to 
use, improve adherence to treatment and thus reduce the chances of 
development of drug resistance. The current national experience shows that bid 
(twice a day) regimens of FDCs are well tolerated and complied with.  
Preferred first line regimen:  
Zidovudine (300 mg) + lamuvidine (150 mg) + Nevirapine(200 mg). 
Zidovudine may cause anaemia, which requires Hemoglobin monitoring, but is 
preferred over Stavudine because of its toxicity (lipoatrophy, lactic acidosis, 
peripheral neuropathy). Patients who develop severe anaemia while on an 
Zidovudine  based regimen should not be re-challenged with Zidovudine. In 
such cases, the patient should receive either Stavudine or Tenofavir (in place of 
Zidovudine. 
Alternative first line regimens 
1) Zidovudine (300 mg) + Lamivudine (150 mg) + Efavirenz (600 mg). 
Efavirenz is substituted for Nevirapine in cases of intolerance to the 
latter or if patients are receiving rifampicin containing anti-TB 
treatment. Efavirenz should not be used in patients with grade 4 or 
higher elevations of ALT. 
2) Stavudine (30 mg) + Lamivudine (150 mg) + Nevirapine (200 mg)/ 
Efavirenz (600 mg). If the patients have anaemia, Stavudine based 
regimen should be prescribed. 
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TREATMENT: CHEMOTHERAPY 
 Treatment of malignancies is site-specific and guided by institutional 
protocol. 
1. Non Hodgkins Lymphoma: Cyclophosphmaide, adriamycin, vincristin, 
prednisolone with or without etoposide . (CHOP or EPOCH). 
2. Cervix: Paclitaxel with Cisplatin. 
3. Breast: Adriamycin, Cyclophospamide with Docetaxel / 5-flurouracil. 
4. Lung :Cisplatin with etoposide , cisplatin with gemcitabine. 
5. Stomach: Cisplatin with 5-flurouracil. 
6. Soft Tissue Sarcoma: Vincristin, adriamycin, cyclophoshamide. 
7. Squamous cell Carcinoma of Buccal mucosa and Conjuctiva : Cisplatin 
with 5-flurouracil. 
8. Hepatocellular carcinoma: 5-flurouracil. 
9. Myeloma: vincristine , adriamycin , dexamethasone. 
Interactions between HAART and Chemotherapy 
1. Lamivudine (3TC) - no contraindication 
2. Zidovudine (ZDV) - increased risk of anaemia and myelosuppression.  
3. Stavudine (d4 T) - possible increased risk of peripheral neuropathy with 
neurotoxic chemotherapy. 
4. . Efavirenz (EFV) - no increased risk of toxicity. 
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5. Nevirapine (NVP) - avoid in individuals receiving hepatotoxic 
chemotherapy. 
Table 4 
Anticancer therapy Primary isoforms 
that 
mediate bio-
transformation 
Interaction 
with NNRTI 
drugs (CYP 
inducers) 
Interaction with PI 
drugs 
(CYP inhibitors) 
Alkylating agents 
Cyclophosphamide  
Ifosfamide  
Lomustine 
 
3A4, 2B6, 2D6 
 3A4 
 3A4 
 
↑ 
↑ 
↑ 
 
_ 
↓ 
↓ 
Anthracyclines 
Doxorubicin  
Mitoxantrone 
 
3A4  
3A4 
 
_ 
_ 
 
↓ 
↓ 
Camptothecins 
Irinotecan  
Topotecan 
 
3A4  
 3A4 
 
↓ 
↑ 
 
↑ 
_ 
Epipophyllotoxins 
Etoposide 
 
3A4 
 
↓ 
 
↑ 
Taxanes 
Docetaxel 
Paclitaxel 
 
3A4  
3A4, 2C8 
 
↓ 
↓ 
 
↑↑ 
↑ 
Vinca alkaloids    
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Vincristine 3A4 ↓ ↑ 
Kinase inhibitor 
Imatinib  
Erlotinib 
 
3A4  
3A4, 1A2 
 
↓ 
↓ 
 
↑ 
↑ 
 
 
 
 
 
 
 
 
 
 
 40
RESULTS 
STUDY POPULATION AND PATIENT CHARACTERISTICS 
 Between August 2009 and July 2010, 36 patients met the eligibility 
criteria of the proposed study and were recruited. The total number of patients 
registered in Medical Oncology department during the same period was 2465. 
Patients with HIV associated Malignancy constituted about 1.46%.  The patient 
characteristics and distribution of malignancy is listed in the Annexure 1. 
Table 5  General Profile 
Character of cancer patients in the study Number Percentage
MALE 1275 1.49 
FEMALE 1190 1.42 
HIV associated cancers 36 1.46 
HIV associated cancers in male 19 52.8 
HIV associated cancers in female 17 47.2 
 
 The median age was 39 years ( Range 10 years to 60 years). Men 
comprised 19 out of 36 patients (52.8 %) and women 17 out of 36 patients 
(47.2 %). AIDS defining malignancies were present in about 47.2% (17 
patients) and non –AIDS defining malignancies were seen in about 52.8 %( 19 
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patients). Men comprised 53% and women 47% in AIDS defining 
malignancies and the same distribution was seen in non-AIDS defining 
malignancies also. 
Table 6  Disease Characteristics 
Character of cancer patients in the study Number Percentage
AIDS defining Malignancy 17 47.2 
AIDS defining Malignancy in males 9 53 
AIDS defining Malignancy in females 8 47 
Non-AIDS defining Malignancy 19 52.8 
Non-AIDS defining Malignancy in males 10 52.6 
Non-AIDS defining Malignancy in females 9 47.4 
Mean age of AIDS related Malignancy              38 years 
Mean age of non-AIDS related Malignancy 43years 
 
 The median time interval between the diagnosis of HIV and Malignancy 
was 37 months (Range 6 months to 120 months). It was observed that 25 out of 
36 patients (70 %) developed malignancies after a period of time, whereas 11 
out of 36 patients (30 %) were diagnosed to have HIV only at the time of 
diagnosing malignancy. Of these 11 patients, four had AIDS defining 
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malignancy (36 %) and seven had non-AIDS defining malignancy (67 %). Of 
the 25 patients with HIV who developed malignancy at a later period, 13 had 
AIDS defining malignancy (52%) and 12 had non-AIDS defining malignancy 
(48 %). 
 All patients except one in this study were adults. The only child was a 
ten year old female child who had contacted HIV from her mother and had a 
time interval of 19 months before she presented with HIV defining malignancy 
of Burkitts lymphoma. 
Table 7  Age Distribution 
Character of cancer patients in the study Number Percentage
Paediatric AIDS related Malignancy  1 2.8 
Adult AIDS related Malignancy 35 97.2 
 . 
All the 11 patients who were diagnosed simultaneously with   HIV and 
Malignancy were started on HAART along with chemotherapy and nine out of 
25 (36 %) patients who were diagnosed to have HIV but were not initiated on 
HAART because of their good CD4 count were also started on HAART along 
with chemotherapy. 
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Table 8 HAART Treatment 
Character of cancer patients in the study Number Percentage
Patients already on HAART 16 44.5 
Patients started on HAART along with chemotherapy 20 55.5 
 
 At the time of beginning the treatment, 23 patients had a Performance 
status 1 by ECOG (64 %) and 13 patients had a Performance status 2 by ECOG 
(36 %). 
Table 9  Performance Status 
Character of cancer patients in the study Number Percentage
ECOG 1 23 64 
ECOG 2 13 36 
  
Multi-drug resistant Tuberculosis and Hepatitis B infection were present 
as co-morbidity in three of these patients in this study. 
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Table 10  Co-morbid Diseases 
Character of cancer patients in the study Number Percentage
HBV coexisting AIDS related Malignancy 1 2.8 
MDR –TB coexisting AIDS related Malignancy 2 5.5 
 
 The mean CD4 count at the time of presentation was 234 (Range 59-
660). The variation between each cycle of chemotherapy was -37, -40, -19, 0 , 
0 (Range 33 to -366, 28 to -167, 79 to -150, 32 to -330, 74 to -144 
respectively). 
Table 11  CD4 Count during treatment 
Median CD4+ COUNT  234 
Variation between successive cycles 74 to -366 
 
 Response assessment for all patients showed a complete response (CR) 
in five patients, partial response (PR) in sixteen patients and death in fifteen 
patients. The longest follow-up of patient was about 18 months (Range 1-18 
months). 
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Table 12 Response Assessment 
Character of cancer patients in the study Number Percentage 
Complete Respone 
Partial Response 
Death 
5 
16 
15 
14 
44 
42 
Follow –up Maximum of 18 months 
(1-18 months) 
 
AIDS Defining Malignancies  
 In accordance to CDC criteria, only four patients had AIDS defining 
malignancy. There were two patients with Carcinoma Cervix, one with Burkitts 
lymphoma and one patient had Plasmablastic variant of DLBCL. AIDS Related 
Lymphomas were also included in this subgroup of patients. While eleven 
patients had DLBCL of primarily nodal type, two had extra nodal DLBCL( one 
in Breast and the other in Buccal mucosa). 
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Table 13 Disease characteristics in ADC and ARL 
Character of cancer patients in the study Number Percentage
Types of AIDS defining Malignancy 
1.Non-Hodgkins  Lymphoma (NHL) – DLBCL 
 
10 
 
28.8 
   Non-Hodgkins  Lymphoma (NHL) –          
PLASMABLASTIC  
1 2.8 
  Non-Hodgkins  Lymphoma (NHL) – BURKITTS 1 2.8 
  Non-Hodgkins  Lymphoma (NHL) – MALT  1 2.8 
  Non-Hodgkins  Lymphoma (NHL) - DLBCL-
BREAST 
1 2.8 
  Non-Hodgkins  Lymphoma (NHL) - DLBCL-
BUCCAL  MUCOSA    
1 2.8 
2. CERVIX 2 5.6 
 
 This group had five patients diagnosed with AIDS and Malignancy at 
presentation. Twelve patients had a time period of 8 to 75 months (median 19 
months) from the time of diagnosing HIV to malignancy. 
 The median initial CD4 count at the first chemotherapy was 220 (range 
59-660). The median change in CD4 count with each cycle of chemotherapy 
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was -38, -41, -20, 0 ,0 (range 5 to -120, 20 to -120, 30 to -150, 32 to -50, 8 to -
144 respectively). 
 Response assessment showed two complete responses, five partial 
responses and eight deaths. Complete response was seen in DLBCL patients, 
one nodal and the other extra nodal (Buccal mucosa). The patient with nodal 
DLBCL who had a CR was later found to have re-activation of Hepatitis B 
virus. 
Table 14  Response in AIDS Defining Malignancies 
RESPONSE Number of Patients 
Complete Response 2 
Partial Response 5 
Death 10 
 
 The follow-up of these patients was up to a maximum of 18 months. 
Both the patients with CR were on regular follow-up while the patients with 
partial response had a follow-up of 1, 3,4,4,5 months before they died of 
malignancy. 
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NON AIDS DEFINING MALIGNANCY 
 Non AIDS defining Malignancy was present in 19 patients. The 
majority presented with Breast cancer (5 patients). Lung, Stomach, Soft Tissue 
Sarcoma and Conjunctival malignancy were two each, while Myeloma, 
Hepatocellular carcinoma, Buccal mucosa, Oral cavity, Paranasal sinuses and 
anal carcinoma were one each. 
Table 15  Disease characteristics in non AIDS defining Malignancy 
Character of cancer patients in the study Number Percentage
Types of non- AIDS defining Malignancy 
1.BREAST  
 
5 
 
14.0 
2.LUNG  2 5.6 
3.STOMACH  2 5.6 
4.MYELOMA  1 2.8 
5.ANAL  CANAL  1 2.8 
6.SOFT TISSUE SARCOMA 1 2.8 
7.HEPATOCELLULAR CARCINOMA 1 2.8 
.8.SQUAMOUS CELL CARCINOMA OF ORAL 
CAVITY 
1 2.8 
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9.SQUAMOUS CELL CARCINOMA OF BUCCAL 
MUCOSA  
1 2.8 
10.SQUAMOUS CELL CARCINOMA OF PARA 
NASAL SINUSES 
1 2.8 
11. SQUAMOUS CELL CARCINOMA OF 
CONJUCTIVA 
2 5.6 
 
 This group had a mean age of 43 years (range21 – 60 years). Thirteen 
patients had time interval of 6 to 120 months (median 51 months) from the time 
of diagnosing HIV to malignancy .This group had six patients diagnosed with 
AIDS and Malignancy at presentation. 
`  The median initial CD4 count at the first chemotherapy was 345 (range 
64-600). The median change in CD4 count with each cycle of chemotherapy 
was -36, -34, -18, 0 ,0 (range 33 to -366, 22 to -167, 79 to -120, 24 to -330, 74 
to -40 respectively). 
 Response assessment showed three complete responses, eleven partial 
responses and five deaths. Complete response was seen in two patients with 
Carcinoma Breast and one in Carcinoma of Oral cavity. 
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Table 16  Response Assessment 
RESPONSE Number of Patients 
Complete Response 3 
Partial Response 11 
Death 5 
 
 The follow-up of these patients was up to a maximum of 15 months. All 
the three patients with CR were on regular follow-up while three patients with 
partial response died after 2, 3, 3 months and others are on regular follow-up. 
ACUTE TOXICITY 
 Acute toxicities were manageable. The most common toxicity observed 
was hematological toxicity. Grade 3 toxicities observed were nausea/ vomiting, 
febrile neutropenia , and hematological toxicity.  
A delay in starting subsequent therapy was observed in 14 patients 
mostly due to febrile neutropenia. The delay was about 7-14 days. Other 
toxicities were managed symptomatically and patients recovered to proceed on 
treatment. 
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Table 17 Type and Frequency of Acute Toxicities observed 
 No of Patients 
Toxicity Grade 1 Grade 2  Grade 3 Grade 4 
Hemoglobin 9 2 1 - 
Leucocytes 16 3 6 - 
Neutrophils 16 2 6 - 
Platelets 6 - - - 
Infection,Febrile 
Neutropenia 
2 6 6 - 
Mucositis 6 3 - - 
Nausea,Vomiting 3 13 3 - 
Renal function - - - - 
Liver function 1 - - - 
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DISCUSSION 
Dramatic and prolonged T-cell depletion following the administration of 
chemotherapy for AIDS-related NHL was described in the pre-HAART era103. 
There has been a study which has shown that the early recovery of lymphocyte 
subsets within 3 months of the end of chemotherapy to pre chemotherapy levels 
and the continued rise of these parameters during prolonged follow-up are 
reassuring, suggesting that combination chemotherapy with HAART can be 
safely delivered without long-term immune suppression. This pattern of 
lymphocyte subset recovery following chemotherapy was similar, although 
probably swifter than that seen in the immunocompetent population104. 
This study has been devised to assess the effect of chemotherapy on 
immunological parameters (CD4+) in patients with malignancy on HAART. 
Our results show that there is a variation in CD4 count during chemotherapy 
and HAART in both AIDS defining Cancers (ADC) and Non AIDS defining 
Cancers (nADC). This has also been documented during chemotherapy in other 
studies. The change in CD4 cell count from the start to end of chemotherapy 
variation in our study was 74 to  -366. The same observation is found in other 
studies 58, 60, 62, 84. The immunological recovery after completion of treatment 
was also studied by the above investigators and they have found that in patients 
who survive, CD4 count improves and reaches the pre-chemotherapy status by 
the third month. 
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Whether the change in CD4 count correlated with survival is the 
question to be answered. In our study, of the five patients who achieved 
complete response, four patients had sustained CD4 count while the fifth 
patient had decreasing CD4 count with a nadir of 99 at the beginning of sixth 
cycle of chemotherapy. In patients with partial response, all patients had a CD4 
count which did not vary much with each cycle of chemotherapy. This leads to 
the group of patients who died during chemotherapy, whose CD4 count 
analysis did show that there was a persistent low CD4 count throughout the 
treatment period.  
The response rates also reveal an interesting observation. The patients 
who presented with a poor performance status, advanced disease and an initial 
low CD4 count had Grade III febrile neutropenia at the end of first cycle itself 
and this lead to delay in subsequent chemotherapy. This was also the group 
who died during treatment.  
AIDS related lymphoma (ARL) was the commonest cancer in our study. 
AIDS related Lymphomas (ARL) has been observed to have a better prognosis 
with the advent of HAART 57-66. All these patients had advanced stage, B 
symptoms, extranodal involvement such as bone marrow and central nervous 
system at the time of presentation. Mortality in AIDS-associated cancers was 
higher when these patients had low CD4 count and Karnofsky performance 
score, presence of extranodal disease, an advanced clinical stage, presence of 
bone marrow involvement, an age more than 35 years and a high serum lactate 
 54
dehydrogenase.  In our study, we found that ARL had a 50% death rate (8 out 
of 15). This observation can be attributed to the above said reasons and also the 
presence of MDR-TB in two of those patients. This is in line with the fact that 
the biology of the primary tumor plays a major role in response105. An 
interesting fact is that there was no patient with  Primary CNS Lymphoma, 
Primary Effusion Lymphoma or Kaposi’s Sarcoma in  our study which is in 
contrast to that as seen in Western countries, where the incidence is high.  
Our results show that there is an increase in Non AIDS defining Cancer 
(nADC).Though Cervical Cancer is a common malignancy in India , we had 
only two patients in this study. This is attributed to the Personian bias of 
referring Carcinoma Cervix to the Women and Children’s Hospital. A notable 
subset was Squamous Cell Carcinoma of the Conjunctiva, which is on a 
increasing trend. Among nADC, Hodgkins Lymphoma , has been observed to 
be increasing in incidence in Western countries due to prolonged survival of 
AIDS patient on HAART (subsequent to increased T cell mileu caused by 
HAART). In our study there was no Hodgkins Lymphoma even though there 
were 16 patients already taking HAART. 
The other method to study the impact of chemotherapy on the 
immunological parameter of HIV infection is to quantify the viral load. The 
studies which have studied the CD4 cell dynamics and chemotherapy had also 
studied the viral load. The trials found a significant decrease during 
chemotherapy of  -1.61 log10 copies/Ml  and  - 2 log10 copies/mL   and -
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2.8log10 copies/mL during chemotherapy with HAART. The study describing 
the maximal responses reports a decline in median HIV viral load from 29 000 
copies/mL at the start of chemotherapy to less than 500 copies/mL. In contrast, 
DA-EPOCH therapy without concomitant HAART was associated with a 
median rise in viral load during chemotherapy of +0.83 log10 copies/mL. (62). 
NACO’s operational guidelines does not allow for measurement of viral load 
except in a scenario where the patient becomes refractory to HAART. 
Another focus of this study was to examine the acute toxicities of the 
treatment. All patients on HAART were initiated with tablet Septran 
(Sulfamethoxazole /trimethoprim ) as a prophylactic measure. Immune 
Reconstitution Inflammatory Syndrome ( IRIS ) observed  in patients after 
starting on HAART was not observed in our study. Grade III hematological 
toxicities observed and life threatening was febrile neutropenia . Other 
toxicities observed were manageable with good supportive care.  
This analysis confirms that chemotherapy and concomitant HAART for 
AIDS-related Malignancies do not cause prolonged suppression of lymphocyte 
subsets.  
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CONCLUSION 
In conclusion , we have identified that 
1) The surrogate parameter to assess  the immune competence of  HIV 
patients is CD4 count , which is found to be varying  with each cycle 
of chemotherapy 
2) The final response outcome depends on the initial CD4 count , 
change in CD4 count between chemotherapy cycles , performance 
status of the patient, pathobiology and aggressiveness of the 
malignancy and opportunistic infection. 
3) Concurrent chemotherapy and HAART has been observed to be 
feasible in our study. 
4) Non AIDS defining Malignancies are increasing in incidence which 
can be attributed to the increased life expectancy with HAART. 
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